Eli Lilly jumps 10% after it says it will seek approval for its Alzheimer's drug following designation as a breakthrough therapy by the FDA

Eli Lilly jumps 10% after it says it will seek approval for its Alzheimer's drug following designation as a breakthrough therapy by the FDA

Business Insider

Published

Goldman Sachs said Eli Lilly's decision to seek accelerated approval for donanemab was ahead of its expectations.

Full Article